EVALUATING THE UPTAKE OF [18F] FLUOROESTRADIOL (FES) BPET/DBT IN PRIMARY BREAST CANCER TO MEASURE THE LOCALIZED EXTENT OF ESTROGEN RECEPTOR POSITIVE DISEASE

The purpose of this study is to test a new scanner device that combines two types of imaging called Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DPT) for imaging of a radioactive imaging drug called 18F-Fluoroestradiol (FES), as a diagnostic device for imaging estrogen receptor (ER) positive breast cancers. FES is a radioactively labeled estrogen imaging drug that is currently FDA approved for use on whole body PET scanners to image ER+ recurrent or metastatic breast cancers. In this study, we want to test FES as a diagnostic imaging drug in primary breast cancer using a new scanning device that combines a smaller PET scanner designed only to image the breast (similar to a mammogram) in combination with a type of imaging used routinely in the clinic, called digital breast tomosynthesis (DBT), which uses x-rays to create images of the breast. The purpose of this study is to test whether the combination of using FES and the dedicated breast scanner BPET/DBT can be a better imaging tool to help diagnosis and determine the size and location of ER+ breast cancers prior to surgery or start of breast cancer treatment.

You may be eligible for this study if you meet the following criteria:

• Conditions: BREAST CANCER
• Age: 18 years - 99 years
• Gender: Female